MARTINSRIED and MUNICH, Germany, May 23, 2014 (GLOBE NEWSWIRE) -- Dr. Walter Blättler re-elected as Supervisory Board Member
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that at the Company's Annual General Meeting on Friday, 23 May 2014, its shareholders approved all proposals of the Company's Management put to vote at the meeting including:
- The carrying forward of the accumulated profit of the 2013 financial year.
- The formal approval of the activities of the members of the Management and Supervisory Boards in respect of the 2013 financial year.
- The appointment of PricewaterhouseCoopers AG as auditor of MorphoSys AG and the MorphoSys Group for the 2014 financial year.
- The creation of a new Authorized Capital 2014-I with the possibility to exclude pre-emptive rights of the shareholders.
- The re-election of Dr. Walter Blättler as a member of the Supervisory Board for one additional year.
- The authorization to purchase treasury shares pursuant to Section 71 para. 1 no. 8 of the German Stock Corporation Act and to use treasury shares with the possibility to exclude pre-emptive rights of the shareholders.
"We are pleased to announce the re-election of Walter Blättler, an experienced member of the Supervisory Board with many years of experience in the development of antibody-based cancer drugs, and look forward to continue working with him," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
At the Annual General Meeting 2014 of MorphoSys AG, 47.81 % of the voting shares were represented.
More information on the Company's Annual General Meeting including the voting results on all agenda points can be found on http://www.morphosys.com/agm.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Specialist Corporate Communications & IR
Jessica Rush
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
Medie Release (PDF) http://hugin.info/130295/R/1788231/614275.pdf
HUG#1788231